Today: 30 April 2026
Browse Category

NYSE:NVO 6 February 2026 - 24 April 2026

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.
24 April 2026
···
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk’s Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly’s Foundayo at 3,707, according to IQVIA data cited by analysts. Novo’s shares rose $2.24 to $40.76, while Lilly’s fell $35.26 to $882.39. Novo said its oral semaglutide lowered HbA1c by 0.83 points more than placebo in a trial of adolescents with type 2 diabetes. The company plans to seek regulatory approval for pediatric use in 2026.
24 April 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
23 April 2026
···
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health shares fell 1.6% to $30.52 Tuesday after Amazon launched a GLP-1 weight-management program through One Medical, intensifying competition in telehealth weight loss. Amazon said its program will offer same-day pharmacy delivery in nearly 3,000 cities and 24/7 prescription renewals. Eli Lilly and Novo Nordisk shares also declined. Hims is shifting away from compounded GLP-1s toward branded, FDA-approved drugs.
21 April 2026
·····
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
12 March 2026
···
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares jumped 5.9% to $23.47 Tuesday after announcing a distribution deal with Novo Nordisk, extending a two-day gain to 49%. Novo withdrew its lawsuit against Hims as part of the pact, which will bring Ozempic and Wegovy to Hims’ platform and phase out most compounded GLP-1 drugs. Analysts raised price targets but warned branded drugs could lower margins. Regulatory risks remain.
11 March 2026
··
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly shares fell 2.3% to $1,028.07 Monday as health stocks lagged, despite the S&P 500 edging higher. Innovent Biologics won Chinese approval for Jaypirca, a Lilly-partnered cancer drug, after late-stage trial results. Investors remain focused on Lilly’s obesity drug pipeline and upcoming FDA decisions, with orforglipron inventory reaching $1.5 billion ahead of a possible U.S. launch.
2 March 2026
····
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82. The company disclosed in its annual report that it faces an SEC investigation, a Justice Department referral, and a patent lawsuit from Novo Nordisk over compounded semaglutide products. BTIG downgraded the stock, citing regulatory risks and weak guidance. Citi cut its price target to $13.25 and maintained a “sell” rating.
26 February 2026
···
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk shares fell 2.5% to 245.1 Danish crowns Tuesday after its CagriSema obesity drug failed to match Eli Lilly’s tirzepatide in a Phase 3 trial. Barclays cut its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo also reported mid-stage China trial results for its “triple G” obesity drug UBT251, showing up to 19.7% weight loss after 24 weeks.
24 February 2026
··
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.
8 February 2026
···
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
7 February 2026
··
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
1 2 3 … 7

Stock Market Today

  • Alphabet Shares Soar to All-Time High with Strong Q1 Earnings, Market Cap Doubles to $4.4 Trillion
    April 30, 2026, 10:36 AM EDT. Alphabet Inc., Google's parent company, reported an 81% surge in Q1 earnings to $62.6 billion and revenues up 22% to $109.9 billion, surpassing estimates. The stock jumped over 6% in after-hours trading, pushing its market capitalization to a record $4.4 trillion, more than double its value from a year ago. Growth was driven by Google's digital ads and a booming Cloud division, which saw a 63% revenue rise. CEO Sundar Pichai emphasized the payoff from large investments in artificial intelligence (AI), with spending on AI data centers and tech projects planned to reach up to $185 billion this year. In contrast, other AI investors like Microsoft and Meta faced stock declines despite strong quarters, illustrating Alphabet's leadership in the AI expansion.

Latest article

Nvidia Isn’t Over. But Marvell Is the Quiet AI Chip Name Analysts Can’t Ignore

Nvidia Isn’t Over. But Marvell Is the Quiet AI Chip Name Analysts Can’t Ignore

30 April 2026
Marvell Technology shares rose about 3% Thursday after Big Tech firms signaled AI spending would exceed $700 billion this year. Nvidia slipped 1.6% but announced a $2 billion investment in Marvell and a partnership on AI infrastructure. Marvell reported record fiscal 2026 revenue of $8.2 billion, while Nvidia posted $215.9 billion for the year. Google is in talks with Marvell to develop two new AI chips.
Is the AI Stock Rally Over? 3 Warning Signs Investors Should Watch This Week

Is the AI Stock Rally Over? 3 Warning Signs Investors Should Watch This Week

30 April 2026
Meta Platforms shares fell nearly 10% and Microsoft dropped over 3% Thursday as investors reacted to rising AI costs and capital spending, despite strong earnings. Alphabet gained almost 6% after Google Cloud posted its best growth quarter. Nvidia and other chip stocks also traded lower. Meta raised its 2026 capex forecast and is considering a major bond sale to fund AI infrastructure.
Go toTop